Article
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
Blood - 8 Aug 2013
Quintás-Cardama Alfonso, Abdel-Wahab Omar, Manshouri Taghi, Kilpivaara Outi, Cortes Jorge, Roupie Anne-Laure, Zhang Su-Jiang, Harris David, Estrov Zeev, Kantarjian Hagop, Levine Ross L, Verstovsek Srdan
Abstract excerpt
Pegylated interferon α-2a (PEG-IFN-α-2a) has previously been shown to induce hematologic and molecular responses in patients with polycythemia vera (PV) or essential thrombocythemia (ET). Here we present a follow-up of a phase 2 trial with PEG-IFN-α-2a treatment in 43 PV and 40 ET patients with detailed molecular analysis. After a median follow-up of 42 months, complete hematologic response was achieved in 76% of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.